



## **TEMPORAL TREND OF HIV/AIDS INCIDENCE AND MORTALITY IN BRAZIL, FROM 2009 TO 2019**

**Maurício Pratzel Ellwanger<sup>1</sup>, Manuela Pozza Ellwanger<sup>2</sup>, Fabiley by Wite Diogo<sup>3</sup>, Liz Andréa Babireski Braz de Oliveira<sup>4</sup>, Debora Reinert<sup>5</sup>, Águida Vita de Souza Diogo<sup>6</sup>, Antônio Carlos Mattar Munhoz<sup>7</sup>, Chaiana Esmeraldino Mendes Marcon<sup>8</sup>.**

### **ABSTRACT**

**Objectives:** To analyze the temporal trend of HIV/AIDS incidence and mortality in Brazil from 2009 to 2019, identifying regional and demographic variations. **Methods:** An ecological time series study using data from the Notifiable Diseases Information System (SINAN) and the Mortality Information System (SIM) of the Ministry of Health. Incidence and mortality rates were calculated for the period from 2009 to 2019. The analysis of temporal trends was performed using linear regression for time series, with a statistical significance level of 95% ( $p < 0.05$ ). **Results:** During the study period, 448,682 new cases of HIV and 132,499 AIDS-related deaths were recorded in Brazil. The South and Southeast regions had the highest incidence and mortality rates. The highest rates were observed in males and in the 30-39 age group. The main cause of death, according to the ICD-10, was related to infectious and parasitic diseases. There was a general trend toward a reduction in HIV/AIDS incidence and mortality during the study period. **Conclusions:** The study identified a trend of reduction in HIV/AIDS incidence and mortality in Brazil between 2009 and 2019, highlighting important regional and demographic variations. These results suggest the effectiveness of public policies, government interventions, and medical advances, such as antiretroviral therapy (ART), in reducing mortality and incidence of the disease.

**Keywords:** Acquired Immunodeficiency Syndrome, HIV Infection, High Activity Antiretroviral Therapy, Antiretroviral Therapy, Incidence, Mortality.

---

<sup>1</sup> University of Contestado – Santa Catarina

<sup>2</sup> University of Contestado – Santa Catarina

<sup>3</sup> University of Contestado – Santa Catarina

<sup>4</sup> University of Contestado – Santa Catarina

<sup>5</sup> University of Contestado – Santa Catarina

<sup>6</sup> University of Contestado – Santa Catarina

<sup>7</sup> Doctor

University of Contestado – Santa Catarina

<sup>8</sup> Dr.

University of Southern Santa Catarina – Santa Catarina



## INTRODUCTION

Since it was introduced in 1981 in California, Acquired Immunodeficiency Syndrome (AIDS) has had an enormous impact on public health due to its unstable and lethal epidemic character. According to the World Health Organization (WHO), by the beginning of 2020, there were approximately 38 million people living with HIV (human immunodeficiency virus) in the world. In Brazil, the first case of AIDS was identified in the 1980s in the cities of São Paulo and Rio de Janeiro. Currently, about 920 thousand people live with HIV in the country. From 2007 to June 2020, Brazil registered 342,459 cases of HIV infection and approximately 39 thousand new cases have been registered annually in the last 5 years. (1–3)

AIDS is the consequence of HIV infection - a retrovirus belonging to the Retroviridae family with RNA genome and Lentivirinae subfamily - which is characterized by tropism by the immune system, with its most evident affectation in CD4 T lymphocytes. HIV can be found in the body fluids of infected people in the form of simple particles or infected immune cells, and its contamination occurs sexually, percutaneously and perinatally. However, 80% of adults acquire the virus after exposure on the surfaces of the mucosa, so AIDS is, first and foremost, a sexually transmitted infection. (4–7)

HIV infection can course with numerous clinical manifestations and does not manifest itself in the same way in all people. In primary exposure to the virus, the seroconversion phase occurs, in which the immune system launches defense mechanisms to control the infection. This leads to clinical manifestations that can range from a flu-like condition to mononucleosis-simile, fever, photophobia, weight loss, cervical adenopathy, erythematous pharyngitis, myalgia, hepatosplenomegaly, diarrhea, nausea, vomiting, and headache. This typically occurs within 2 to 4 weeks after infection, thus marking the period of exacerbation. The duration of symptoms is approximately 1 to 2 weeks and they are self-limiting. After acquiring humoral immunity against HIV, which takes about 3 to 12 weeks, the body goes through a phase of viremic stabilization known as set point. In this phase there is a decrease in the viral load, as a result of the direct action of the immune system, entering into clinical latency characterized by being an asymptomatic period that can last up to 10 years. (5,8,9)

AIDS mortality in Brazil is a relevant problem for Public Health. From the 80s, the beginning of the AIDS epidemic, until the end of 2020, 360,323 deaths were reported with HIV/AIDS as the underlying cause, with a higher number of deaths among men. However, in the last 10 years there has been a decrease in the mortality coefficient of the disease in the country, which may be associated with governmental and non-governmental actions

---

such as: provision of antiretroviral treatment, prevention and treatment of opportunistic diseases, increase in the network of diagnostic services and strategies for adherence to the prevention and treatment of the disease. (10–13)

The change in the pattern of AIDS mortality is also related to the advances in medicine that occurred in the mid-90s, in which there was the introduction of drugs capable of modifying the action of the virus in the body at different stages of the replicative cycle, making it possible to redefine the concept of deadly disease to chronic. By the year 2020, approximately 642 thousand people were on antiretroviral treatment, 48,406 more, compared to 2018. Even with the change in the panorama of the disease, AIDS continues to have a high lethality, being the fifth cause of death in adults. (14–16)

In view of the above, the temporal analysis of HIV/AIDS incidence and mortality in Brazil is of paramount importance to contribute to the deepening of knowledge of this disease, which is still so relevant to the country. Therefore, this study aimed to analyze the temporal trend of HIV/AIDS incidence and mortality in Brazil, from 2009 to 2019.

## METHODS

An ecological time-series study of HIV/AIDS incidence and mortality rates in Brazil from 2009 to 2019 was conducted.

The study population was composed of all people who died in Brazil from the cited cause and new reported cases (selected according to "year of diagnosis" on the platform), in the period from 2009 to 2019, whose secondary data were aggregated in the Mortality Information System of the Ministry of Health (SIM-MS) and in the Information System of Diseases and Notifications (SINAN), Datasus. Cases whose variables of interest had unknown or unavailable data were excluded from the study.

The following were evaluated in the study: number of deaths and new cases due to HIV/AIDS in the period between 2009 and 2019; sex (female or male); age group (15 to 39 years; 40 to 49 years; 50 to 59 years; 60 years or older); regions of Brazil (North, Northeast, Midwest, Southeast and South); ICD10 category (B20, B21, B22, B23, B24).

The calculations of mortality and incidence rates were carried out by the ratio between the number of deaths or new cases registered and the resident population at risk in the territory in the years 2009 to 2019, the result was multiplied by the constant 100 thousand following the following formula:

Incidence rate = ((number of new cases) (by year, sex, or region of residence) and year of diagnosis (2009-2019) /(population at risk residing in Brazil in the years 2009-2019)) x 100,000

Mortality rate = ((number of deaths) (by year, sex, or region of residence) and year of occurrence (2009-2019) / (population at risk residing in Brazil in the years 2009-2019)) x 100,000

The data were obtained from the DATASUS website, selected from TABNET and tabulated and organized in a database created and analyzed with the aid of Microsoft Excel® version 365 software.

The variables were described as mean and standard deviation and the evolutionary behavior of the mean annual variation of the values of the series ( $\beta$ ) was tested by the linear regression method for time series. The analysis of the period was performed using the ANOVA test and with Pearson's correction coefficient and its significance. The level of statistical significance was 95%, with a p-value < 0.05.

As this is a study that uses secondary databases with population aggregates, and there was no research subject, there was no possibility of physical or moral damage. Thus, in accordance with CNS Resolution 466/12, the present study did not require submission to the Research Ethics Committee of the Universidade do Sul de Santa Catarina (CEP UNISUL).

The authors declare that there are no conflicts of interest between the research topic and their professional activities or those related to the funding of this research.

## RESULT

Between 2009 and 2019, 448,682 new cases of HIV and 132,499 deaths were registered in Brazil, with a mortality rate of 50.9 deaths per 100 thousand inhabitants in the country. The highest absolute values for incidence and mortality were found in the Southeast region, while the highest rates were recorded in the South region. In both regions, downward trends were demonstrated, according to the mean annual variation by linear regression (Beta), for the incidence ( $\beta = -0.99$  and  $-0.93$ , respectively) and mortality ( $\beta = -0.96$  and  $-0.95$ , respectively) rates, both with statistical significance ( $p < 0.05$ ), evidencing a strong negative relationship between time and event. The Central-West region also showed this same trend, but without statistical significance for the period. The other regions showed an upward trend, as shown in tables 1 and 2.

The analysis of HIV/AIDS incidence rates in Brazil, segmented by major Brazilian regions in the period from 2009 to 2019, reveals significant variations between regions. Table 1 presents these annual incidence rates, highlighting the annual percentage variation (VA%) for each region. There is a general trend of reduction in incidence rates in some regions, while others show an increase or stability over the period studied.

Table 1: HIV/AIDS incidence rate in Brazil, according to major Brazilian region, from 2009 to 2019.

Year	Brazilian Region									
	North	VA%	Northeast	VA%	Southeast	VA%	South	VA%	Midwest	VA%
2009	20,92	-	14,15	-	23,22	-	32,84	-	18,55	-
2010	21,85	0,04	14,74	0,04	22,50	-0,03	32,40	-0,01	18,69	0,01
2011	21,46	-0,02	15,39	0,04	23,18	0,03	34,71	0,07	20,06	0,07
2012	21,87	0,02	16,16	0,05	22,00	-0,05	33,65	-0,03	21,05	0,05
2013	25,99	0,19	16,52	0,02	20,69	-0,06	32,25	-0,04	20,63	-0,02
2014	26,45	0,02	16,04	-0,03	19,88	-0,04	30,20	-0,06	19,40	-0,06
2015	25,00	-0,05	16,00	0,00	19,05	-0,04	29,23	-0,03	18,19	-0,06
2016	25,42	0,02	15,63	-0,02	18,17	-0,05	26,22	-0,10	17,50	-0,04
2017	23,52	-0,07	15,95	0,02	17,43	-0,04	24,69	-0,06	18,12	0,04
2018	25,48	0,08	16,37	0,03	16,46	-0,06	23,62	-0,04	17,81	-0,02
2019	26,37	0,04	15,90	-0,03	15,52	-0,06	23,17	-0,02	19,24	0,08
Average	24,03		15,71		19,83		29,36		19,02	
$p$	0,01		0,03		0,00		0,00		0,22	
$R_s$	0,76		0,65		-0,99		-0,93		-0,40	
$R^2$	0,58		0,42		0,97		0,87		0,16	
$\beta$	0,76		0,65		-0,99		-0,93		-0,40	

Source: TABNET (DATASUS), adapted by the author.

Observations: VA% = annual percentage change;  $p$  = p-value;  $R_s$  = Pearson's Degree of Correlation;  $R^2$  = coefficient of determination;  $\beta$  = Mean Annual Change by linear regression.

In addition to incidence rates, HIV/AIDS mortality rates also show important regional variations in Brazil during the period from 2009 to 2019. Table 2 details these mortality rates, showing the annual percentage variation (VA%) for each major Brazilian region. The data indicate a general trend of reduction in mortality, although some regions showed fluctuations or increases in rates during the period analyzed.

Table 2: HIV/AIDS mortality rate in Brazil, according to the large Brazilian region, from 2009 to 2019.

Year	Region									
	North	VA%	Northeast	VA%	Southeast	VA%	South	VA%	Midwest	VA%
2009	5,25	-	3,93	-	7,27	-	9,50	-	5,07	-
2010	5,92	0,13	3,88	-0,01	7,20	-0,01	9,45	0,00	5,51	0,09
2011	5,75	-0,03	4,13	0,06	7,07	-0,02	9,34	-0,01	4,99	-0,09
2012	5,53	-0,04	4,33	0,05	6,79	-0,04	9,11	-0,03	5,35	0,07
2013	6,67	0,21	4,50	0,04	6,56	-0,03	9,18	0,01	4,90	-0,09
2014	6,75	0,01	4,39	-0,02	6,64	0,01	8,78	-0,04	4,90	0,00
2015	6,72	0,00	4,74	0,08	6,34	-0,04	8,69	-0,01	5,38	0,10
2016	7,19	0,07	4,73	0,00	6,15	-0,03	8,28	-0,05	5,22	-0,03
2017	6,91	-0,04	4,56	-0,04	5,44	-0,12	7,91	-0,05	5,09	-0,03
2018	6,75	-0,02	4,38	-0,04	5,23	-0,04	7,23	-0,09	4,81	-0,05
2019	6,51	-0,04	4,33	-0,01	4,78	-0,08	6,83	-0,06	4,58	-0,05
Average	6,36		4,36		6,32		8,57		5,07	
$p$	0,00		0,03		0,00		0,00		0,11	
$R_s$	0,78		0,67		-0,96		-0,95		-0,52	
$R^2$	0,61		0,44		0,93		0,90		0,27	
$B$	0,78		0,67		-0,96		-0,95		-0,52	

Source: TABNET (DATASUS), adapted by the author.

Observations: VA% = annual percentage change;  $p$  = p-value; Rs = Pearson's Degree of Correlation;  $R^2$  = coefficient of determination;  $\beta$  = Mean Annual Change by linear regression.

When evaluating incidence and mortality by sex, it is possible to notice higher rates for males, with a downward trend for both sexes, especially in mortality for females ( $\beta = -0.86$ ). Despite this, the incidence data are significant only for females ( $p < 0.05$ ), while the mortality data for both, as shown in Table 3.

Table 3: HIV/AIDS incidence and mortality rate in Brazil, according to sex, from 2009 to 2019.

Year	Incidence by sex				Mortality by sex			
	Male	VA%	Female	VA%	Male	VA%	Female	VA%
2009	26,12	-	16,62	-	8,31	-	4,27	-
2010	26,19	0,00	15,73	-0,05	8,25	-0,01	4,22	-0,01
2011	27,54	0,05	16,03	0,02	8,15	-0,01	4,20	-0,01
2012	27,42	0,00	15,48	-0,03	7,97	-0,02	4,19	0,00
2013	28,36	0,03	15,06	-0,03	8,36	0,05	4,19	0,00
2014	27,82	-0,02	13,98	-0,07	8,40	0,01	4,05	-0,03
2015	27,57	-0,01	12,82	-0,08	8,30	-0,01	4,14	0,02
2016	26,62	-0,03	11,95	-0,07	8,11	-0,02	4,10	-0,01
2017	26,28	-0,01	11,18	-0,06	7,59	-0,06	3,76	-0,08
2018	25,95	-0,01	10,82	-0,03	7,31	-0,04	3,47	-0,08
2019	25,41	-0,02	10,61	-0,02	6,88	-0,06	3,32	-0,04
Average	26,85		13,66		7,97		3,99	
$p$	0,30		0,00		0,01		0,00	
Rs	-0,34		-0,98		-0,75		-0,86	
R2	0,12		0,96		0,57		0,74	
B	-0,34		-0,98		-0,75		-0,86	

Source: TABNET (DATASUS), adapted by the author.

Observations: VA% = annual percentage change;  $p$  = p-value; Rs = Pearson's Degree of Correlation;  $R^2$  = coefficient of determination;  $\beta$  = Mean Annual Change by linear regression.

Considering the age group, there is a higher incidence rate (Table 4) for the 30 to 39 years and 40 to 49 years age groups, both with statistical significance ( $p < 0.05$ ) and a downward trend for the period ( $\beta = -0.60$  and  $-0.66$ , respectively). On the other hand, the extremes of age,  $< 20$  years and  $\geq 60$  years, have the lowest incidences, but with an increasing trend for age groups between 20 and 29 years and  $\geq 60$  years ( $\beta = 0.63$  and  $0.22$ , respectively) for the period. Mortality rates (Table 5) follow a similar pattern, but with an increasing trend only for the age group  $\geq 60$  years ( $\beta = 0.94$ ).

Table 4: HIV/AIDS incidence rate in Brazil, by age group, from 2009 to 2019.

Year	Age											
	<20	VA%	20 to 29	VA%	30 to 39	VA%	40 to 49	VA%	50 to 59	VA%	60 or more	VA%
2009	2,57	-	25,89	-	47,00	-	41,64	-	25,75	-	8,99	-
2010	2,50	-0,03	26,21	0,01	44,25	-0,06	40,72	-0,02	25,89	0,01	8,47	-0,1
2011	2,53	0,01	27,50	0,05	45,77	0,03	41,99	0,03	25,87	0,00	9,05	0,07
2012	2,58	0,02	28,42	0,03	43,59	-0,05	39,85	-0,05	25,60	-0,01	9,09	0



2013	2,65	0,03	29,82	0,05	42,47	-0,03	39,36	-0,01	26,04	0,02	9,82	0,08
2014	2,61	-0,02	29,44	-0,01	40,14	-0,05	37,02	-0,06	25,04	-0,04	9,39	-0
2015	2,49	-0,04	29,31	0,00	38,09	-0,05	34,48	-0,07	24,60	-0,02	9,20	-0
2016	2,33	-0,07	28,25	-0,04	35,49	-0,07	32,96	-0,04	23,21	-0,06	9,32	0,01
2017	2,22	-0,05	29,30	0,04	33,65	-0,05	30,50	-0,07	22,25	-0,04	9,11	-0
2018	1,99	-0,10	28,45	-0,03	33,01	-0,02	30,15	-0,01	21,64	-0,03	9,28	0,02
2019	1,96	-0,02	28,52	0,00	31,88	-0,03	29,23	-0,03	21,11	-0,02	8,83	-0
Average	2,40		28,28		39,58		36,17		24,27		9,14	
<i>p</i>	0,00		0,04		0,00		0,00		0,00		0,52	
<i>Rs</i>	-0,82		0,63		-0,98		-0,97		-0,92		0,22	
<i>R</i> <sup>2</sup>	0,67		0,39		0,97		0,95		0,85		0,05	
<i>B</i>	-0,82		0,63		-0,98		-0,97		-0,92		0,22	

Source: TABNET (DATASUS), adapted by the author.

Observations: VA% = annual percentage change; *p* = p-value; *Rs* = Pearson's Degree of Correlation; *R*<sup>2</sup> = coefficient of determination; *β* = Mean Annual Change by linear regression.

The analysis of HIV/AIDS mortality rates in Brazil, segmented by age group in the period from 2009 to 2019, reveals important variations between different age groups. Table 5 presents these annual mortality rates, highlighting the percentage annual variation (VA%) for each age group. The data indicate a general trend of reduction in mortality rates in some age groups, while others show fluctuations over the analyzed period.

Table 5: HIV/AIDS mortality rate in Brazil, according to age group, from 2009 to 2019.


Year	Age group											
	<20	VA%	20 to 29	VA%	30 to 39	VA%	40 to 49	VA%	50 to 59	VA%	60 or more	VA%
2009	0,35	-	4,68	-	13,28	-	15,21	-	9,93	-	4,04	-
2010	0,35	-0,13	4,41	-0,06	12,69	-0,04	14,97	-0,02	10,13	0,02	4,46	0,11
2011	0,30	0,10	4,31	-0,02	12,46	-0,02	14,76	-0,01	10,02	-0,01	4,40	-0,01
2012	0,33	0,02	4,33	0,00	11,33	-0,09	14,88	0,01	9,82	-0,02	4,62	0,05
2013	0,34	-0,11	4,65	0,07	11,20	-0,01	14,79	-0,01	10,52	0,07	4,92	0,06
2014	0,30	0,10	4,45	-0,04	10,86	-0,03	14,33	-0,03	10,80	0,03	5,25	0,07
2015	0,33	-0,24	4,40	-0,01	10,76	-0,01	13,67	-0,05	11,03	0,02	5,41	0,03
2016	0,25	0,04	4,50	0,02	10,03	-0,07	13,35	-0,02	10,89	-0,01	5,57	0,03
2017	0,26	-0,23	4,28	-0,05	8,93	-0,11	11,93	-0,11	10,29	-0,05	5,42	-0,03
2018	0,20	-0,01	3,92	-0,08	8,40	-0,06	11,22	-0,06	9,64	-0,06	5,49	0,01
2019	0,20	-1,00	3,58	-0,09	7,67	-0,09	10,43	-0,07	9,17	-0,05	5,49	0,00
Average	0,29		4,32		10,69		13,59		10,20		5,01	
<i>p</i>	0,00		0,01		0,00		0,00		0,72		0,00	
<i>Rs</i>	-0,88		-0,71		-0,985		-0,93		-0,13		0,94	
<i>R</i> <sup>2</sup>	0,77		0,50		0,97		0,87		0,02		0,88	
<i>B</i>	-0,88		-0,71		-0,99		-0,93		-0,13		0,94	

Source: TABNET (DATASUS), adapted by the author.

Observations: VA% = annual percentage change; *p* = p-value; *Rs* = Pearson's Degree of Correlation; *R*<sup>2</sup> = coefficient of determination; *β* = Mean Annual Change by linear regression.

When evaluating the mortality rates according to the ICD-10 category in HIV/AIDS patients, it is observed that the main causes of death are related to infectious and parasitic diseases, followed by HIV-related neoplasms, as shown in Figure 1.

Figure 1: HIV/AIDS mortality rate in Brazil, according to ICD-10 category, from 2009 to 2019.



Source: TABNET (DATASUS), adapted by the author. Observations: B20 – HIV disease resulting in infectious and parasitic diseases; B21 – HIV disease resulting in malignant neoplasms; B22 - HIV disease resulting in other specified diseases; B23 - HIV disease resulting in other diseases; B24 - HIV disease not specified.

## DISCUSSION

HIV is an important public health problem in Brazil, as the country has one of the highest prevalences in Latin America. (17) It is estimated that currently about 802,482 people live with the virus in the country. (18) However, even with this significant number, there is a downward trend in the incidence during the study period, which is predominant in the South and Southeast regions. Despite this, the same regions showed the highest incidence rates, in agreement with the 2021 HIV/AIDS Epidemiological Bulletin. (12) Such relationships were already found in other studies and in the period from 1990 to 2002 in Brazil. (19,20) The higher rates found in the aforementioned states can be related to the quality of health care, patient access to the system, and, therefore, higher rates of diagnosis and case notification. As for the decrease in incidence, it is possibly related to efforts to promote, prevent and educate in health in the population.

The mortality rate follows the same slopes as the incidence: higher rates and a more significant downward trend for the South and Southeast regions. Other studies have already shown this, with the states of Rio Grande do Sul, Rio de Janeiro, São Paulo and Santa Catarina having the highest mortality rates in Brazil and the states of São Paulo and Santa Catarina standing out for the decrease in rates. (11–13) In the period of this study,






there is, therefore, a reduction in HIV/AIDS mortality in the country. Research suggests that this reduction may be associated with encouraging the implementation of public policies in the area, such as: improving the quality of public services, reducing vertical transmission of HIV, increasing diagnostic coverage and treatment, reducing stigma and increasing actions for prevention of the population. (21) In agreement with the above, in the same period, a significant increase in the number of people living with HIV using Antiretroviral Therapy (ART) has been described, from 214,726 in 2009 to 633,699 in 2019. (18) To reinforce this suggestion, the study by Cunha, which evaluates the temporal trend of HIV/AIDS mortality from 1990 to 2002, demonstrates the beginning of the decrease in the HIV mortality rate in Brazil from 1997 onwards, a period that coincides with the universal introduction of ART. (19) It is therefore possible to note the importance and effectiveness of ART and public measures related to health care to increase the survival of patients with HIV/AIDS.

As a consequence of the reduction in mortality and the greater number of people treated, there is a tendency for HIV to change from a highly lethal disease to a chronic condition, which is demonstrated by the increase in prevalence, therefore survival, and reduction in the lethality of the disease. (22)

Figure 2 illustrates the case fatality rate and prevalence of HIV/AIDS in Brazil from 2009 to 2019. This figure provides a comprehensive view of the evolution of the disease in the country, highlighting both the lethality rate and the absolute number of people living with HIV, based on data from the AIDS indicator and clinical monitoring system. Prevalence considers people linked to the system, that is, those who have at least one dispensation, CD4 or viral load registered.

Figure 2: Case fatality rate and prevalence of HIV/AIDS in Brazil, from 2009 to 2019.



Source: TABNET (DATASUS)/ Clinical indicators AIDS, adapted by the author. Note: Prevalence is represented by the absolute number of people living with HIV linked (those who have at least one dispensation, CD4, or viral load in the AIDS indicator and clinical monitoring system).

When evaluating the gender variable, it is possible to note that both incidence and mortality are higher for males, a relationship already found by other authors. It is known that men tend to have more advanced stages of the disease, have later diagnoses and start treatment later, which could justify such findings. (13,18,22–25)

The incidence of HIV was predominant in the age group of 30 to 39 years, corroborating other studies in the country(13,17,19,25), but the highest mortality rate is between 40 and 49 years of age. Among all age groups, the only one with an upward trend in mortality was for the elderly, which has already been demonstrated in other studies in Brazil. For Cunha, this may be related to the advance in the use of ART with a consequent increase in life expectancy and advances in diagnosis in the elderly. (13,26) Rossi found a higher chance of death for individuals over 50 years of age, and associates it with the difficulty of early diagnosis and a higher incidence of comorbidities in this age group. (22) The difficulty in diagnosis can be related to the stigma of the disease in the elderly, the difficulty of professionals in addressing sexuality among the elderly, and the confounding factor associated with the symptoms of pre-existing comorbidities and the onset of HIV manifestation. In addition, since it is a sexually transmitted infection, it is usually not among the first hypotheses in medical reasoning in elderly patients, which could delay diagnosis, start of treatment and increase mortality in this age group.

Regarding HIV/AIDS mortality according to the ICD-10 category (including categories B20 to B24), it is noted that the main cause of mortality results from infectious or parasitic diseases, similar to the cohort carried out in northeastern Brazil and in an Amazonian study. (27,28) In that study, as well as in others conducted in Brazil, the main infection associated with HIV/AIDS mortality was tuberculosis. (27,29) It is noteworthy that HIV-positive individuals have immunological fragility due to dysregulation of the immune system with depletion of CD4+ lymphocytes, which favors the emergence of opportunistic infections, the main ones being tuberculosis, cryptococcal meningitis, pneumocystosis, toxoplasmosis,

and cytomegalovirus rhinitis. (14,30) This condition is probably associated with the leading cause of death found in the studies.

The present study has advantages mainly to guide public policies contributing to the management and planning of prevention actions and care for people living with HIV/AIDS, since it provides relevant information on population groups. Despite this, it finds limitations related to the accessed databases that may be incomplete or inconsistent. In addition, it is not possible to extrapolate the present findings to specific individuals or groups.

## **CONCLUSION**

The present study demonstrates a temporal trend of reduction in HIV/AIDS incidence and mortality in Brazil in the period from 2009 to 2019. Among the Brazilian states, those with the highest incidence and mortality rates were the South and Southeast, which also showed the greatest downward trends. It was possible to notice a predominance of the disease in males and aged 30 to 39 years, while mortality was predominantly observed in males and in the age group of 40 to 49 years. The leading cause of death in HIV/AIDS was the result of infectious and parasitic diseases.

With the present study, it is possible to note that the disease is still very important for Brazilian public health, despite the drop in lethality. This finding is possibly related to the popularization and efficacy of ART, which makes HIV/AIDS a chronic disease, increasing its prevalence and reducing mortality.

Finally, even with an optimistic scenario for the future of controlling the incidence, treatment and mortality of HIV/AIDS, there is still a need for public programs for population education, prevention and encouragement of early detection and treatment of the disease in the country.

## REFERENCES

1. Alves, D. N., Costa, L. M., & Vieira, N. V. (2017). Use of coding causes of death in HIV in the classification of deaths in Northeast Brazil. *\*Revista de Saúde Pública, 51\**, 1–9. <https://doi.org/10.11606/S1518-8787.2017051000124>
2. Brazil. Ministry of Health, Health Surveillance Secretariat, Department of Surveillance, Prevention and Control of Sexually Transmitted Infections, HIV/AIDS and Viral Hepatitis. (2018). *\*Clinical protocol and therapeutic guidelines for the management of HIV infection in adults\**. Ministério da Saúde. <http://www.aids.gov.br/>
3. Chambers, L. A., Wilson, M. G., Rueda, S., Gogolishvili, D., Shi, M. Q., & Rourke, S. B. (2014). Evidence informing the intersection of HIV, aging, and health: A scoping review. *\*AIDS and Behavior, 18\**(4), 661–675. <https://doi.org/10.1007/s10461-013-0627-5>
4. da Cunha, A. P., da Cruz, M. M., & Pedroso, M. (2022). Analysis of the trend of mortality by HIV/AIDS according to sociodemographic characteristics in Brazil, 2000 to 2018. *\*Ciência & Saúde Coletiva, 27\**(3), 895–908. <https://doi.org/10.1590/1413-81232022273.00432021>
5. da Silva Magno, E., Saraceni, V., & Coeli, C. M. (2017). Factors associated with TB/HIV coinfection: Evidence from notification data in the State of Amazonas, Brazil, 2001–2012. *\*Cadernos de Saúde Pública, 33\**(5), 1–11. <https://doi.org/10.1590/0102-311X00019315>
6. Dartora, W. J., Propp, Â. É., & Ribeiro Pavão, L. (2017). Prevalence of HIV in Brazil 2005–2015: Data from the Unified Health System. *\*Revista Cuidarte, 8\**(3), 1919. <https://doi.org/10.15649/cuidarte.v8i3.462>
7. de Melo, M. C., de Almeida, V. C., & Donalísio, M. R. (2021). Trend incidence of HIV-AIDS according to different diagnostic criteria in Campinas-SP, Brazil from 1980 to 2016. *\*Ciência & Saúde Coletiva, 26\**(1), 297–307. <https://doi.org/10.1590/1413-81232020261.08652019>
8. de Rossi, S. M. G., Goulart, F. C., & Nascimento, M. C. (2012). Impact of antiretroviral therapy according to different AIDS treatment consensuses in Brazil. *\*Pan American Journal of Public Health, 32\**(2), 117–123. <https://doi.org/10.1590/S1020-49892012000800005>
9. Dias, J. O., Gabryelle, S., Sousa, C. D., Rômulo, D., & Furtado, L. (2019). Main symptoms and immunological alterations resulting from HIV infection: A literature review. *\*Unpublished manuscript\**, 1–11.
10. Dourado, I., Maria, M. A., Barreira, D., & de Brito, A. M. (2006). Trends in the AIDS epidemic in Brazil after antiretroviral therapy. *\*Revista de Saúde Pública, 40\**(Suppl.), 9–17. <https://doi.org/10.1590/S0034-89102006000700003>
11. Gomes, C. D. Q. (2015). *\*Human immunodeficiency virus: The development of a vaccine\** [Unpublished doctoral dissertation]. Fernando Pessoa University.
12. Jiang, H., Yin, J., Fan, Y., Liu, J., Zhang, Z., Liu, L., & Nie, S. (2015). Gender difference in advanced HIV disease and late presentation according to European consensus definitions. *\*Scientific Reports, 5\**, 14543. <https://doi.org/10.1038/srep14543>



13. Magno, E. da S., Ferreira, A. C., & Silva, L. M. (2019). Causes of death related to HIV/AIDS in a reference institution, Amazonas, 2016. *\*Brazilian Journal of Health Review, 2\*(2), 787–799.* <https://brjd.com.br/index.php/BJHR/article/view/1216/1081>
14. Marins, J. R. P., Jamal, L. F., Chen, S. Y., Barros, M. B., Hudes, E. S., Barbosa, A. A., Chequer, P., Teixeira, P. R., & Hearst, N. (2003). Dramatic improvement in survival among adult Brazilian AIDS patients. *\*AIDS, 17\*(11), 1675–1682.* <https://doi.org/10.1097/00002030-200307250-00012>
15. Ministério da Saúde. (2018). *\*Technical manual for the diagnosis of HIV infection in adults and children\**. Secretaria de Vigilância em Saúde. <http://www.aids.gov.br/>
16. Ministério da Saúde. (2021). *\*Data on AIDS in Brazil\**. Secretaria de Vigilância em Saúde. <http://www.aids.gov.br/>
17. Ministério da Saúde. (2021). *\*HIV/AIDS epidemiological bulletin | 2021\**. Secretaria de Vigilância em Saúde. <http://www.aids.gov.br/>
18. Ministério da Saúde. (2022). *\*Clinical indicators AIDS in Brazil\**. Secretaria de Vigilância em Saúde. <http://indicadoresclinicos.aids.gov.br/>
19. Myhre, J., & Sifiris, D. (2021). Symptoms of HIV. *\*Very Well Health\**. <https://www.verywellhealth.com/hiv-aids-symptoms-4014373>
20. Reis, A. C., Santos, E. M. dos, & Cruz, M. M. da. (2007). Mortality for AIDS in Brazil: An exploratory study of its temporal evolution. *\*Epidemiologia e Serviços de Saúde, 16\*(3), 195–205.*
21. Salomão, R. (2017). *\*Infectologia: Bases clínicas e tratamento\** (Vol. 1). GEN - Grupo Editora Nacional.
22. Santiago, G. M. F. (2020). *\*Mortality from opportunistic infections in HIV-positive patients\** [Unpublished doctoral dissertation]. Federal University of the Southern Border.
23. Santos, F. F. dos, Pereira, F. B., Silva, C. L. O. da, Lazzarotto, A. R., & Petersen, R. D. de S. (2013). Immunological and virological characteristics and the variables flexibility (FLEX) and abdominal resistance strength (FRA) of children and adolescents with HIV/AIDS using ART. *\*Revista Brasileira de Medicina do Esporte, 19\*(1), 40–43.* <https://doi.org/10.1590/S1517-86922013000100008>
24. Shiels, M. S., & Engels, E. A. (2017). Evolving epidemiology of HIV-associated malignancies. *\*Current Opinion in HIV and AIDS, 12\*(1), 6–11.* <https://doi.org/10.1097/COH.0000000000000327>
25. Soares, R., Armindo, R. D., & Rocha, G. (2014). Immunodeficiency and the immune system: Behavior in HIV carriers. *\*Arquivos de Medicina, 28\*(4), 113–121.*
26. Sousa, A. I. A. de, & Pinto, V. L. (2016). Spatial and temporal analysis of AIDS cases in Brazil in 1996–2011: Areas of increased risk over time. *\*Epidemiologia e Serviços de Saúde, 25\*(3), 467–476.* <https://doi.org/10.5123/S1679-49742016000300003>
27. UNAIDS. (2021). *\*Global statistics on HIV\**. <https://unaids.org.br/estatisticas/>
28. UNAIDS, & World Health Organization. (2007). *\*2007 AIDS epidemic update\**. [http://data.unaids.org/pub/EPISlides/2007/2007\\_epiupdate\\_en.pdf](http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf)

29. Villarinho, M. V., Almeida, R. M., & Silva, L. C. (2013). Public health policies in the face of the AIDS epidemic and assistance to people with the disease. \*Revista Brasileira de Enfermagem, 66\*(2), 271–277.
30. Weber, A., Silva, J. R., & Santos, M. C. (2020). Analysis of the temporal trend of HIV/AIDS infection in the western region of Santa Catarina: A retrospective study 1984–2015. \*Journal of Epidemiology and Infection Control, 10\*(1), 1–8. <https://doi.org/10.17058/jeic.v1i1.13089>